Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is projected to post its resultson Wednesday, May 13th. Analysts expect Sunshine Biopharma to post earnings of ($0.16) per share and revenue of $9.20 million for the quarter.
Sunshine Biopharma Stock Performance
Shares of NASDAQ SBFMW opened at $0.14 on Tuesday. Sunshine Biopharma has a twelve month low of $0.05 and a twelve month high of $0.45. The company has a 50 day moving average of $0.13 and a 200 day moving average of $0.17.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Further Reading
- Five stocks we like better than Sunshine Biopharma
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
